medcelerator · clinician one-pager
First FDA-Approved Treatment for Ataxia in Ataxia-Telangiectasia
Aqneursa (levacetylleucine) — oral suspension for ataxia in ataxia-telangiectasia
FDA Approved · United States · September 21, 2026
Condition: Ataxia-Telangiectasia
Who this is for
This is for people living with ataxia-telangiectasia — and the caregivers who help them — who weigh at least 15 kg and may be candidates for labelled US Aqneursa oral suspension for ataxia. It explains the first FDA-approved A-T ataxia therapy (18 Sep 2026), the IB1001-303 fSARA results, weight-based packet dosing, embryo-fetal and fall/laceration honesty, AQNEURSA Cares navigation, and why authorised is not funded — without treating Aqneursa as a cure for immunodeficiency or cancer risk, treating completed research as walk-in enrolment, or importing US packets. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/aqneursa-levacetylleucine-ataxia-telangiectasia